Journal article
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
WZ Yeh, PA Widyastuti, A Van der Walt, J Stankovich, E Havrdova, D Horakova, K Vodehnalova, S Ozakbas, S Eichau, P Duquette, T Kalincik, F Patti, C Boz, M Terzi, BI Yamout, J Lechner-Scott, P Sola, OG Skibina, M Barnett, M Onofrj Show all
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
Abstract
Objective To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included pregnancies conceived after December 31, 2010, in women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses. Results We included 1,998 pregnancies from 1,619 women with MS. Preconception annualized relapse rate (ARR) was 0.29 (95% confidence interval 0.27-0.32), fell to 0.19 (0.14-0.24) in the third trimester, and increased to 0.59 (0.51-0.67) in early postpartu..
View full abstractRelated Projects (1)
Grants
Awarded by Merck
Funding Acknowledgements
Funding provided by the NHMRC of Australia, grant 1156519; Multiple Sclerosis Research Australia Postgraduate Scholarship, No. 19-0735; and Australian Government Research Training Program Scholarship. MSBase is a not-for-profit organization that receives support from Roche, Merck, Biogen, Novartis, Bayer-Schering, Sanofi Genzyme, and Teva.